IASO Bio Launches FUCASO CAR-T Therapy in Singapore
Singapore and Nanjing, China, November 4, 2026 IASO Bio has officially launched FUCASO (equecabtagene autoleucel) in Singapore, marking an...
BCMA
Advertisement
AbbVie Seeks FDA Approval for Etentamig in Myeloma Treatment
North Chicago, Illinois, USA, October 27, 2026 AbbVie has submitted a Biologics License Application (BLA) to the U.S. Food...
CREATE Medicines and WestGene Expand In Vivo CAR Pipeline
Cambridge, Massachusetts, U.S., October 26, 2026 CREATE Medicines, Inc. has announced a strategic research and development collaboration and licensing...
C4 Therapeutics Presents Cemsidomide Biomarker Data in Multiple Myeloma
WATERTOWN, Mass. — September 25, 2026 C4 Therapeutics presented new biomarker data from clinical trials of cemsidomide in patients...
Johnson & Johnson TECVAYLI Gains Positive CHMP Opinion
Raritan, New Jersey, U.S., September 18, 2026 Johnson & Johnson has announced that the European Medicines Agency’s Committee for...
Advertisements
AbelZeta’s C-CAR168 Receives FDA IND Clearance
San Diego, California, U.S., September 14, 2026 AbelZeta Therapeutics has announced that the U.S. Food and Drug Administration (FDA)...
BMS Reports Positive Phase 2 CAR T Cell Trial Results
Princeton, New Jersey, U.S., September 8, 2026 Bristol Myers Squibb (BMS) has announced positive topline results from the registrational...
AbbVie Reports Positive Phase 3 Etentamig Results
North Chicago, Illinois, USA, September 3, 2026 AbbVie has announced positive topline results from the Phase 3 CERVINO trial,...
Johnson & Johnson Expands TECVAYLI for Multiple Myeloma Care
Beerse, Belgium, August 21, 2026 Johnson & Johnson announced that the European Commission (EC) has approved an indication extension...
Leads Biolabs’ Partner Oblenio Bio Doses First Patients in Phase 1a Trial of LBL-051
NANJING, China, August 4, 2026 Leads Biolabs announced that its partner Oblenio Bio, a company jointly established with Aditum...
Advertisement
